Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Understanding the effects of Gender Affirming Hormone Therapy (GAHT) on immune function using a systems immunology approach

Award Number: R21AI179004
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/22/2023
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Understanding the effects of Gender Affirming Hormone Therapy (GAHT) on immune function using a systems immunology approach - PROJECT SUMMARY One million individuals in the United States identify as transgender (0.39% of population), of which 90% are either on gender-affirming hormone therapy (GAHT) or considering starting GAHT. Understanding how feminizing GAHT (estradiol) and masculinizing GAHT (testosterone) influence immune function is imperative, considering that (i) transgender women have a significantly increased prevalence of Human Immunodeficiency Virus (HIV) infection worldwide and (ii) little is known about how GAHT influences immune function or susceptibility to infections. To address this gap in knowledge, our team will combine established state-of-the-art systems immunology approaches to a completed longitudinal cohort of transgender women before and during GAHT. We previously used this longitudinal model to show that both feminizing and masculinizing GAHT induced DNA methylation changes at specific genomic loci in whole peripheral blood, some of which were previously associated with puberty or pregnancy. In the first three aims of this project, we will use viably stored peripheral blood mononuclear cells from transgender women at baseline, and 3 and 6 months following GAHT. By applying a systems immunology approach, we first seek to establish how GAHT changes the circulating immune profile and plasma metabolites, both of which are predictors of response to infection and vaccines. Next, innate, and adaptive immune function will be assessed through in vitro stimulation with a range of microbial and viral microbes, specifically HIV, followed by cytokine assays. Finally, in Aim 3 we will map the underlying epigenomic profile of specific immune cell types, by profiling active histone modifications and open chromatin at single cell level. Together, the above approach will identify the key molecular drivers of altered immune function in response to GAHT and generate new hypotheses for further study. Ultimately, understanding how GAHT alters the molecular biology of immune cells will open new avenues to therapeutic intervention in cases where immune function is compromised because of GAHT. In aim 4, we will use our established longitudinal GAHT recruitment strategy to establish a cohort of transgender individuals with extensive biospecimen collection. This will allow us to explore the effects of GAHT on the vaginal and fecal microbiota and stress, which are known modulators of immunity. Once established, this longitudinal cohort will provide opportunities to apply a range of state-of-the-art molecular and immunophenotyping techniques to understand if and how GAHT affects susceptibility to HIV infection.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $120,516 )
2024	2024	MURDOCH CHILDREN'S RESEARCH INSTITUTE	ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD	PARKVILLE				AUS	Allergy and Infectious Diseases Research	001	2	8/16/2024	NON-COMPETING CONTINUATION	$0
2024	2024	MURDOCH CHILDREN'S RESEARCH INSTITUTE	ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD	PARKVILLE				AUS	Allergy and Infectious Diseases Research	000	2	8/2/2024	NON-COMPETING CONTINUATION	$120,516
														Subtotal = $120,516

Issue Date FY: 2023 ( Subtotal = $151,363 )
2023	2023	MURDOCH CHILDREN'S RESEARCH INSTITUTE	ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD	PARKVILLE				AUS	Allergy and Infectious Diseases Research	000	1	8/22/2023	NEW	$151,363
														Subtotal = $151,363

Grand Total All Awards = $271,879

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Understanding the effects of Gender Affirming Hormone Therapy (GAHT) on immune function using a systems immunology approach

Award Number: R21AI179004

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/22/2023

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer